Sadik H. Kassim, PhD Mustang Bio

Dr. Sadik Kassim has served as Chief Scientific Officer of Mustang Bio since March 2018.  Sadik joined Mustang in March 2017 as Vice President of Process and Analytical Development, where he led process development, analytical development and manufacturing strategy for Mustang’s CAR T therapies and oversaw preclinical research and pipeline expansion activities. Prior to Mustang, Sadik was Head of Analytical Development for Novartis’ Cell and Gene Therapies Unit in Cambridge, Massachusetts where he contributed the Biologics License Application filing for Kymriah™ (CD19 CAR T) in pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.  Earlier in his career, Dr. Kassim was a research biologist in the Surgery Branch at the National Cancer Institute, where he was involved in early research and CMC work that led to the development of Kite’s Yescarta™ (CD19 CAR T) for lymphoma.  Sadik held a senior research position in the Discovery Immunology Group at Johnson & Johnson and was a research fellow in the University of Pennsylvania’s (Penn) Gene Therapy Program where he led the initial discovery efforts and pre-clinical studies for an AAV8 gene therapy for familial hypercholesteromia.  This program is now in the clinic as part of RegenexBio’s RGX-501 program.